Elritercept (KER-050)
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Arms / Cohorts
Experimental:Part 1, Cohort 1: Elritercept
Accepting patients
Experimental:Part 2, Cohort B: Elritercept Dose Confirmation
Accepting patients
Experimental:Part 1, Cohort 3: Elritercept
Accepting patients
Experimental:Part 2, Cohort C: Elritercept Dose Confirmation
Accepting patients
Experimental:Part 1, Cohort 5: Elritercept
Accepting patients
Experimental:Part 2, Cohort E: Elritercept Dose Confirmation
Accepting patients
Experimental:Part 2, Cohort G: Elritercept Dose Confirmation
Accepting patients
Experimental:Part 2, Cohort F: Elritercept Dose Confirmation
Accepting patients
Experimental:Part 2, Cohort A: Elritercept Dose Confirmation
Accepting patients
Experimental:Part 1, Cohort 2: Elritercept
Accepting patients
Experimental:Long-term Extension Cohort
Accepting patients
Experimental:Part 1, Cohort 4: Elritercept
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.